Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory Myelofibrosis
John Mascarenhas(Mount Sinai Hospital), Maciej Kaźmierczak(Silesian University of Technology), Viola Maria Popov(Clinical Emergency Hospital Bucharest), Wayne Rothbaum, Jesse McGreivy(Pharmacyclics (United States)), Hope Qamoos(Soleno Therapeutics (United States)), Zübeyde Nur Özkurt(Gazi University), Sanjay Mohan(Breast Cancer Research Foundation), Haifa Kathrin Al‐Ali(University Hospital in Halle), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Zhuying Huang(Soleno Therapeutics (United States)), Andrew C. Perkins(The University of Queensland), Jean‐Jacques Kiladjian(Assistance Publique – Hôpitaux de Paris)
Cited by 15
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890